Article
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Future oncology (London, England) - 1 May 2020
Lin Huamao M, Pan Xiaoyun, Hou Peijie, Allen Susan, Baumann Pia, Hochmair Maximilian J
Abstract excerpt
Aim: To assess time-to-treatment discontinuation (TTD) of brigatinib following treatment with ALK tyrosine kinase inhibitor(s) (TKIs) in patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving brigatinib through the international early access program. Patients & analysis: Analysis was performed for patients with ALK+ NSCLC treated with prior ALK TKIs, including next-generation ALK TKIs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.